Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$24.7M
Filings
399
Firms Hired
13
Active Period
1999–2020
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Lower Costs, More Cures Act of 2019
2019 · fourth_quarter · Firm: THE MCMANUS GROUP
Medicare Part B drugs payments and access. S. 551, the REFUND Act, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 19
Elijah E. Cummings Lower Drug Costs Now Act
2019 · fourth_quarter · Firm: THE MCMANUS GROUP
Medicare Part B drugs payments and access. S. 551, the REFUND Act, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3
Hatch-Waxman Integrity Act of 2019
2019 · fourth_quarter · Firm: THE MCMANUS GROUP
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 990
Hatch-Waxman Integrity Act of 2019
2019 · fourth_quarter · Firm: THE MCMANUS GROUP
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 344
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 440
Medicare Part B drugs payments and access. S. 551, the REFUND Act, H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $60,000
Matched citations: S. 551
Elijah E. Cummings Lower Drug Costs Now Act
2019 · third_quarter · Firm: THE MCMANUS GROUP
Medicare Part B drugs payments and access. S. 551, the REFUND Act, S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3
Hatch-Waxman Integrity Act of 2019
2019 · third_quarter · Firm: THE MCMANUS GROUP
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 990
Prescription Drug Pricing Reduction Act of 2019
2019 · third_quarter · Firm: THE MCMANUS GROUP
Medicare Part B drugs payments and access. S. 551, the REFUND Act, S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2543
Hatch-Waxman Integrity Act of 2019
2019 · third_quarter · Firm: THE MCMANUS GROUP
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 344
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 440
Medicare Part B drugs payments and access. S. 551, the REFUND Act, S. 2543, the Prescription Drug Pricing Reduction Act, and H.R. 3, the Lower Drug Costs Now Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 551
Hatch-Waxman Integrity Act of 2019
2019 · second_quarter · Firm: THE MCMANUS GROUP
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 990
Hatch-Waxman Integrity Act of 2019
2019 · second_quarter · Firm: THE MCMANUS GROUP
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 344
S. 440, the PACED Act. Support for H.R. 990/S. 344, the Hatch-Waxman Integrity Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 440
Medicare Part B drugs payments and access. S. 551, the REFUND Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 551
A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents.
2017 · fourth_quarter · Firm: THE MCMANUS GROUP
Patent issues related to biopharmaceuticals, including S. 1948 - A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents.
Client expense: — · Firm income: $60,000
Matched citations: S. 1948
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: THE MCMANUS GROUP
FDA approval and enforcement issues. Support for Sec. 604 (B)(b) of H.R. 2430 - FDA Reauthorization Act of 2017. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 2430
FDA approval and enforcement issues. Support for Sec. 604 (B)(b) of H.R. 2430 - FDA Reauthorization Act of 2017. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $60,000
Matched citations: S. 934
Drug Diversion and Counterfeit Crackdown Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
S.934, Food and Drug Administration Reauthorization Act; HR 2376, Drug Diversion and Counterfeit Crackdown Act of 2017
Client expense: — · Firm income: $30,000
Matched citations: HR 2376
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
S.934, Food and Drug Administration Reauthorization Act; HR 2376, Drug Diversion and Counterfeit Crackdown Act of 2017
Client expense: — · Firm income: $30,000
Matched citations: S.934
Drug Diversion and Counterfeit Crackdown Act of 2017
2017 · second_quarter · Firm: THE MCMANUS GROUP
FDA approval and enforcement issues. Support for H.R. 2376 - Drug Diversion and Counterfeit Crackdown Act of 2017. Support for Sec. 604 of H.R. 2430 FDA Reauthorization Act of 2017. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 2376
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: THE MCMANUS GROUP
FDA approval and enforcement issues. Support for H.R. 2376 - Drug Diversion and Counterfeit Crackdown Act of 2017. Support for Sec. 604 of H.R. 2430 FDA Reauthorization Act of 2017. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 2430
FDA approval and enforcement issues. Support for H.R. 2376 - Drug Diversion and Counterfeit Crackdown Act of 2017. Support for Sec. 604 of H.R. 2430 FDA Reauthorization Act of 2017. Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017.
Client expense: — · Firm income: $60,000
Matched citations: S. 934
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to FDA drug approval process, FDA user fee agreements, S. 934 and counterfeiting.
Client expense: — · Firm income: $30,000
Matched citations: S. 934
Source: Senate LDA